This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Used in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received 1 to 3 prior lines of therapy (CONT.)
Current FDA-Related Drug Information WARNING: DISTANT SPREAD OF TOXIN EFFECT • Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose. http://www. 
WARNINGS AND PRECAUTIONS Immune-Mediated Endocrinopathies Hypophysitis
• Hypophysitis occurred in 2 (0.5%) of 411 patients, consisting of one grade 2 and one grade 4 case (0.2% each), in patients receiving Keytruda in trial 1. The time to onset was 1.7 months for the patient with grade 4 hypophysitis and 1.3 months for the patient with grade 2 hypophysitis. Both patients were treated with high-dose (≥40 mg prednisone or equivalent per day) corticosteroids followed by a corticosteroid taper and remained on a physiologic replacement dose. • Monitor for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency). Administer corticosteroids for grade 2 or greater hypophysitis. Withhold Keytruda for moderate (grade 2) hypophysitis, withhold or discontinue Keytruda for severe (grade 3) hypophysitis, and permanently discontinue Keytruda for life-threatening (grade 4) hypophysitis. Thyroid Disorders • Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) patients, respectively, receiving Keytruda in trial 1. The median time to onset was 1.5 months (range 0.5-2.1). The median duration was 2.8 months (range 0.9-6.1). One of 2 patients with grade 2 and the 1 patient with grade 3 hyperthyroidism required initial treatment with high-dose corticosteroids (≥40 mg prednisone or equivalent per day) followed by a corticosteroid taper. The median time to onset of hypothyroidism was 3.5 months (range 0.7 weeks to 19 months). No patient received corticosteroids or discontinued Keytruda for management of hypothyroidism. • Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. • Administer corticosteroids for grade 3 or greater hyperthyroidism, withhold Keytruda for severe (grade 3) hyperthyroidism, and permanently discontinue Keytruda for lifethreatening (grade 4) hyperthyroidism. Isolated hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids.
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